Fos-related antigen 1 (Fra-1) (Fra-1)

Fra-1 (Fos-related antigen 1) is a basic leucine zipper (bZIP) transcription factor encoded by the FOSL1 gene and a key component of the Activator Protein-1 (AP-1) complex [1, 5]. It primarily functions by heterodimerizing with members of the JUN family to regulate the expression of genes involved in cell proliferation, differentiation, and survival [1, 6]. In oncology, Fra-1 is a well-recognized driver of aggressive tumor phenotypes, particularly through its role in promoting Epithelial-to-Mesenchymal Transition (EMT), invasion, and metastatic dissemination in cancers such as triple-negative breast cancer, lung adenocarcinoma, and glioblastoma [4, 8, 10]. Its activity is tightly regulated by oncogenic signaling pathways, most notably the MAPK/ERK cascade, which enhances both its transcription and protein stability [8, 16]. Although traditionally considered "undruggable" due to the absence of a small-molecule binding pocket, current therapeutic strategies focus on indirect inhibition via upstream kinase inhibitors, RNA-based silencing, and emerging technologies like PROTAC-mediated degradation [4, 8, 34]. Beyond its role in malignancy, Fra-1 is essential for normal bone development and immune cell function, which presents both therapeutic opportunities and potential safety challenges in drug development [1, 2, 16].

Other names

FOSL1Fos-like antigen 1Fos-related antigen 1FRA1FRA-1

Inhibition of DNA binding activity, suppression of gene expression via MAPK/ERK pathway inhibition, promotion of proteasomal degradation (PROTACs), and interference with AP-1 dimerization.